Relapsing Neuromyelitis Optica Spectrum Disorder – Pipeline Review, 2019

Relapsing neuromyelitis optica spectrum disorder, also called neuromyelitis optica or Devic disease, is an autoimmune inflammatory disorder that affects the central nervous system. It is categorized by axonal damage and serious immune-mediated demyelination preferentially targeting spinal cord and optic nerves. Relapsing neuromyelitis optica spectrum disorder is often confused with multiple sclerosis during the early stage. The symptoms of relapsing neuromyelitis optica spectrum disorder are either myelitis or optic neuritis, resulting in pain inside the eye and spine or limbs, respectively.

The standard treatment for acute attacks is high-dose corticosteroids such as methylprednisolone. Plasma exchange can also be done for patients experiencing severe attacks and are not responding to corticosteroids. Drugs such as azathioprine, rituximab, and mycophenolate mofetil are often prescribed for the long term management of neuromyelitis optica.

Lack of drugs for the proper treatment, rising prevalence of the disorder, and active government support has resulted in significant investment by pharmaceutical companies and research institutes for clinical study on the relapsing neuromyelitis optica spectrum disorder. For instance; Satralizumab, a type of interleukin is being studied by F. Hoffmann-La Roche Ltd. and is currently in phase 3 clinical trials for the treatment of relapsing neuromyelitis optica spectrum disorder.

At present, around 41% of the pipeline candidates for relapsing neuromyelitis optica spectrum disorder are in phase 1 clinical stage. More than half of the studies are sponsored by the pharmaceutical industry.

Report Description

The report on ‘Relapsing Neuromyelitis Optica Spectrum Disorder – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Relapsing Neuromyelitis Optica Spectrum Disorder. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Relapsing Neuromyelitis Optica Spectrum Disorder.

The report on ‘Relapsing Neuromyelitis Optica Spectrum Disorder – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

• Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Relapsing Neuromyelitis Optica Spectrum Disorder
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Relapsing Neuromyelitis Optica Spectrum Disorder
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary